Solid Biosciences Reports Inducement Grant to New Chief Legal Officer
04 mars 2021 07h35 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces Appointments to Management Team and Board of Directors
04 mars 2021 07h30 HE
|
Solid Biosciences Inc.
-Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life...
Efficacy and Safety Data from Solid Biosciences’ Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference
24 févr. 2021 16h24 HE
|
Solid Biosciences Inc.
-IGNITE DMD Principal Investigator, Dr. Barry Byrne, to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18- -Company to host external key opinion leaders at a...
Solid Biosciences to Present at Upcoming Investor Conferences
17 févr. 2021 07h30 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference
06 janv. 2021 07h30 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces $90 Million Private Placement
11 déc. 2020 07h30 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update
05 nov. 2020 07h00 HE
|
Solid Biosciences Inc.
–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021– -Collaboration with Ultragenyx creates opportunities to develop additional gene therapies for Duchene muscular...
Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020
03 nov. 2020 07h30 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference
02 oct. 2020 07h30 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
01 oct. 2020 07h30 HE
|
Solid Biosciences Inc.
– Modifications to IGNITE DMD trial protocol and improvements to manufacturing processes enable continued program development – CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences...